武汉佰乐博生物技术有限公司
   
     
联系热线
  • 联系人:方经理
  • 电 话:027-65279366
  • 邮箱:products@biolabreagent.com
  • 地 址:武汉市东湖新技术开发区神墩四路666号C栋

肺癌及卵巢癌潜力靶点SLC34A2/NaPi2b

发表时间:2025-03-05


一、中文名称:肺癌及卵巢癌潜力靶点SLC34A2/NaPi2b相关蛋白抗体


二、产品描述

肺癌及卵巢癌潜力靶点SLC34A2/NaPi2b相关蛋白抗体,1214日欧盟委员会(EC)将MersanaNaPi2b ADC药物upifitamab rilsodotinUpRi)指定为治疗卵巢癌的孤儿药。NaPi2b靶点在肺癌及卵巢癌中发挥了重要作用。


三、相关产品

Anti-Human SLC34A2/NaPi2b Polyclonal Antibody (PHB65401)

Recombinant Human SLC34A2/NaPi2b Protein, N-His-SUMO (YHB65403)

Anti-Human SLC34A2/NaPi2b Antibody (SAA0766) (FHB65410)

Recombinant Human SLC34A2/NaPi2b Protein, N-GST (YHB65402)

Research Grade Anti-Human SLC34A2/NaPi2b (XMT-1592) (DHB65403)

Recombinant Human SLC34A2/NaPi2b, N-His (YHB65401)

Anti-Human SLC34A2/ NaPi2b Polyclonal Antibody (PHB65402)


四、产品详情

名称:Anti-SLC34A2/NaPi2b Polyclonal Antibody (PHB65401)

别名:NaPi2b,Sodium/phosphate cotransporter 2B, Na(+)-dependent phosphate cotransporter 2B, Na(+)/Pi cotransporter 2B, Sodium-dependent phosphate transport protein 2B, NaPi3b, NaPi-2b, SLC34A2, Solute carrier family 34 member 2, Sodium-phosphate transport protein 2BSLC34A2蛋白抗体,NaPi2b蛋白抗体

货号:PHB65401

种属反应性:Human, Rat

宿主:Rabbit

同种型:IgG

克隆类型:Polyclonal

免疫原:E. coli - derived recombinant Human SLC34A2/NaPi2b (Ser251-Asp361).

经测试应用:ELISA: 1:4000-1:8000, IHC: 1:50-1:100, WB: 1:1000-1:4000

靶标:Sodium/phosphate cotransporter 2B, Na(+)-dependent phosphate cotransporter 2B, Na(+)/Pi cotransporter 2B, Sodium-dependent phosphate transport protein 2B, NaPi3b, NaPi-2b, SLC34A2, Solute carrier family 34 member 2, Sodium-phosphate transport protein 2B

纯化方式:Purified by antigen affinity column.

Accession号:O95436

应用:ELISA, IHC, WB

状态:Liquid

保存溶液:0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.

稳定性和存储:Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. (PHB65401)


四、参考文献:

SLC34A2 promotes cancer proliferation and cell cycle progression by targeting TMPRSS3 in colorectal cancer. PMID: 34929599

The role of SLC34A2 in intestinal phosphate absorption and phosphate homeostasis. PMID: 30343332

Knockdown of SLC34A2 inhibits cell proliferation, metastasis, and elevates chemosensitivity in glioma. PMID: 30592329

Characterization of SLC34A2 as a Potential Prognostic Marker of Oncological Diseases. PMID: 34944522

SLC34A2 simultaneously promotes papillary thyroid carcinoma growth and invasion through distinct mechanisms. PMID: 32005974

The SLC34A2-ROS-HIF-1-induced up-regulation of EZH2 expression promotes proliferation and chemo-resistance to apoptosis in colorectal cancer. PMID: 30038060

New insights in the genetic variant spectrum of SLC34A2 in pulmonary alveolar microlithiasis; a systematic review. PMID: 37259144

SLC34A2 Gene mutation of pulmonary alveolar microlithiasis: report of four cases and review of literatures. PMID: 23164546

Impaired phosphate transport in SLC34A2 variants in patients with pulmonary alveolar microlithiasis. PMID: 35443721

SLC34A2 promotes neuroblastoma cell stemness via enhancement of miR-25/Gsk3beta-mediated activation of Wnt/beta-catenin signaling. PMID: 30868061

SLC34A2 promotes cell proliferation by activating STX17-mediated autophagy in esophageal squamous cell carcinoma. PMID: 38720472

SLC34A2 Targets in Calcium/Phosphorus Homeostasis of Mammary Gland and Involvement in Development of Clinical Mastitis in Dairy Cows. PMID: 38731279

Knockdown of SLC34A2 Inhibits Hepatocellular Carcinoma Cell Proliferation and Invasion. PMID: 28281971

Constitutive depletion of Slc34a2/NaPi-IIb in rats causes perinatal mortality. PMID: 33846411

SLC34A2 regulates miR-25-Gsk3beta signaling pathway to affect tumor progression in gastric cancer stem cell-like cells. PMID: 29178392

Is SLC34A2 Associated With Concomitant Calcium Metabolism Disorder in Pulmonary Alveolar Microlithiasis (PAM)? PMID: 37217383

SLC34A2 Up-regulation And SLC4A4 Down-regulation Correlates With Invasion, Metastasis, And The MAPK Signaling Pathway In Papillary Thyroid Carcinomas. PMID: 34405007

Phosphate dysregulation via the XPR1-KIDINS220 protein complex is a therapeutic vulnerability in ovarian cancer. PMID: 35437317

Eight novel variants in the SLC34A2 gene in pulmonary alveolar microlithiasis. PMID: 31831582

SLC34A2 Regulates the Proliferation, Migration, and Invasion of Human Osteosarcoma Cells Through PTEN/PI3K/AKT Signaling. PMID: 28777670

CD74/SLC34A2-ROS1 Fusion Variants Involving the Transmembrane Region Predict Poor Response to Crizotinib in NSCLC Independent of TP53 Mutations. PMID: 38070598

Overexpression of SLC34A2 is an independent prognostic indicator in bladder cancer and its depletion suppresses tumor growth via decreasing c-Myc expression and transcriptional activity. PMID: 28151475

NaPi2b expression in a large surgical Non-Small Cell Lung Cancer (NSCLC) cohort. PMID: 34953676

Antibody-Drug Conjugates in Gynecologic Cancer. PMID: 37229642

(213)Bi/(211)At-Labeled MX35, an anti-sodium-dependent phosphate transport protein 2b (NaPi2b) murine monoclonal antibody. PMID: 22675742

Toward a Topology-Based Therapeutic Design of Membrane Proteins: Validation of NaPi2b Topology in Live Ovarian Cancer Cells. PMID: 35911971

Sodium-dependent phosphate transporter NaPi2b as a potential predictive marker for targeted therapy of ovarian cancer. PMID: 34504954

Development of potent non-acylhydrazone inhibitors of intestinal sodium-dependent phosphate transport protein 2b (NaPi2b). PMID: 35917765

Design, synthesis and biological evaluation of novel pyridine derivatives as gut-selective NaPi2b inhibitors. PMID: 35346844

Inhibition of sodium/hydrogen exchanger 3 in the gastrointestinal tract by tenapanor reduces paracellular phosphate permeability. PMID: 30158152

Discovery of Gut-Restricted Small-Molecule Inhibitors of Intestinal Sodium-Dependent Phosphate Transport Protein 2b (NaPi2b) for the Treatment of Hyperphosphatemia. PMID: 35034442

Development of monoclonal antibodies specific for the human sodium-dependent phosphate co-transporter NaPi2b. PMID: 18724815

Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancer. PMID: 32534811

Immunohistochemical analysis of NaPi2b protein (MX35 antigen) expression and subcellular localization in human normal and cancer tissues. PMID: 21956469

The study of phosphate transporter NAPI2B expression in different histological types of epithelial ovarian cancer. PMID: 19300415

In silico analysis and immunohistochemical characterization of NaPi2b protein expression in ovarian carcinoma with monoclonal antibody Mx35. PMID: 22553815

Advances in antibody-drug conjugates for gynecologic malignancies. PMID: 36484278


详情请咨询Antibodysystem中国授权总代理-武汉佰乐博生物技术有限公司

网址:https://www.antibodysystem.com/product/16940.html

武汉佰乐博生物技术有限公司作为法国Antibodysystem品牌亚洲区授权总代理。提供近3万种蛋白、抗体等核心生命科学试剂,旨在为生命科学科研工作者提供专业、全面、可靠的试剂产品。

试剂 | 耗材 | 定制 | 实验服务 | 供应链

免费热线:027-65279366 /18108604356


联系方式
手机:18108604356
微信扫一扫